BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26871782)

  • 1. Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Retrospective Cohort Study.
    Chung SR; Choi YJ; Kim HS; Park JE; Shim WH; Kim SJ
    Medicine (Baltimore); 2016 Feb; 95(6):e2624. PubMed ID: 26871782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary central nervous system lymphoma in an immunocompetent patient: report of a case].
    Coronel F D; Gallardo V C; Gamargo G C
    Rev Med Chil; 2008 Apr; 136(4):491-5. PubMed ID: 18769792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
    Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
    J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
    Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
    J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate.
    Jang SJ; Lee KH; Lee JY; Choi JY; Kim BT; Kim SJ; Kim WS
    Clin Nucl Med; 2012 Oct; 37(10):e241-4. PubMed ID: 22955084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
    Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
    J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.
    Nguyen PL; Chakravarti A; Finkelstein DM; Hochberg FH; Batchelor TT; Loeffler JS
    J Clin Oncol; 2005 Mar; 23(7):1507-13. PubMed ID: 15735126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI.
    Kim HS; Kwon SL; Choi SH; Hwang I; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
    Eur Radiol; 2020 Apr; 30(4):2171-2181. PubMed ID: 31953664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
    Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
    J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment.
    Zhang Y; Zhang Q; Wang XX; Deng XF; Zhu YZ
    Clin Radiol; 2016 Oct; 71(10):1018-1029. PubMed ID: 27341986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
    Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
    BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
    Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
    J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
    Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
    Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.
    Aoki H; Ogura R; Tsukamoto Y; Okada M; Natsumeda M; Isogawa M; Yoshida S; Fujii Y
    Neurol Med Chir (Tokyo); 2013; 53(11):797-804. PubMed ID: 24162244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL).
    Weigel R; Senn P; Weis J; Krauss JK
    Clin Neurol Neurosurg; 2004 Mar; 106(2):82-7. PubMed ID: 15003295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.